ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AVEO Oncology announces FDA acceptance for filing of an NDA for Tivozanib as treatment of relapsed o
June 04, 2020AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib ... -
AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis
April 01, 2020AVEO Oncology and Biodesix announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab. -
Kyowa Kirin buys back Tivozanib rights from AVEO oncology
August 04, 2019Kyowa Kirin will reobtain the non-oncology rights of tivozanib in AVEO territories excluding the rights which are currently sublicensed to EUSA Pharma -
AVEO Oncology warns of "regulatory action" by EMA if overall survival results for Fotivda come up short
April 04, 2019AVEO Oncology disclosed in a filing with the US Securities and Exchange Commission that the European Medicines …… -
AVEO Oncology Announces Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
June 22, 2017AVEO Oncology announced the company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target of 322
Pharma Sources Insight January 2025
